This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cutler, N. R. Articles by Herting, R. L. Search for Related Content PubMed Articles by Cutler, N. R. Articles by Herting, R. L. Social Bookmarking                         What's this?

Evaluation of Multiple Doses of Milacemide in the Treatment of Senile Dementia of the Alzheimer's Type

California Clinical Trials (Drs Cutler and Sramek), Beverly Hills, CA, Searle Research and Development (Drs Fakouhi and Herting), Skokie, IL, the Pacific Northwest Clinical Research Center (Dr Smith), Portland, OR, the Indiana University Medical Center (Dr Hendrie), Indianapolis, IN, and the University of Utah School of Medicine (Dr Matsuo), Salt Lake City, UT.

T. Daniel Fakouhi, PhD, MBA

California Clinical Trials (Drs Cutler and Sramek), Beverly Hills, CA, Searle Research and Development (Drs Fakouhi and Herting), Skokie, IL, the Pacific Northwest Clinical Research Center (Dr Smith), Portland, OR, the Indiana University Medical Center (Dr Hendrie), Indianapolis, IN, and the University of Utah School of Medicine (Dr Matsuo), Salt Lake City, UT.

Ward T. Smith, MD

California Clinical Trials (Drs Cutler and Sramek), Beverly Hills, CA, Searle Research and Development (Drs Fakouhi and Herting), Skokie, IL, the Pacific Northwest Clinical Research Center (Dr Smith), Portland, OR, the Indiana University Medical Center (Dr Hendrie), Indianapolis, IN, and the University of Utah School of Medicine (Dr Matsuo), Salt Lake City, UT.

Hugh C. Hendrie, MD

California Clinical Trials (Drs Cutler and Sramek), Beverly Hills, CA, Searle Research and Development (Drs Fakouhi and Herting), Skokie, IL, the Pacific Northwest Clinical Research Center (Dr Smith), Portland, OR, the Indiana University Medical Center (Dr Hendrie), Indianapolis, IN, and the University of Utah School of Medicine (Dr Matsuo), Salt Lake City, UT.

Fumisuke Matsuo, MD

California Clinical Trials (Drs Cutler and Sramek), Beverly Hills, CA, Searle Research and Development (Drs Fakouhi and Herting), Skokie, IL, the Pacific Northwest Clinical Research Center (Dr Smith), Portland, OR, the Indiana University Medical Center (Dr Hendrie), Indianapolis, IN, and the University of Utah School of Medicine (Dr Matsuo), Salt Lake City, UT.

John J. Sramek, PharmD

California Clinical Trials (Drs Cutler and Sramek), Beverly Hills, CA, Searle Research and Development (Drs Fakouhi and Herting), Skokie, IL, the Pacific Northwest Clinical Research Center (Dr Smith), Portland, OR, the Indiana University Medical Center (Dr Hendrie), Indianapolis, IN, and the University of Utah School of Medicine (Dr Matsuo), Salt Lake City, UT.

Robert L. Herting, MD, PhD

California Clinical Trials (Drs Cutler and Sramek), Beverly Hills, CA, Searle Research and Development (Drs Fakouhi and Herting), Skokie, IL, the Pacific Northwest Clinical Research Center (Dr Smith), Portland, OR, the Indiana University Medical Center (Dr Hendrie), Indianapolis, IN, and the University of Utah School of Medicine (Dr Matsuo), Salt Lake City, UT.

A multicenter, double-blind, placebo-controlled, parallel group study was conducted to assess the safety and efficacy of three doses of milacemide in the treatment of patients with senile dementia of the Alzheimer type of mild to moderate severity. Patients were randomly assigned to receive one of three dosages of milacemide (400, 800, or 1200 mg/day) or placebo for 4 weeks followed by a single-blind 4-week placebo period. One hundred forty-eight men and women older than 50 years of age were enrolled, and 129 patients completed the study. The differences among treatment groups were not statistically different with respect to total scores on the Alzheimer's Disease Assessment Scale or any items and subscales that were examined, nor were significant differences on the Clinical Global Impression Scale found. Clinically significant increases in liver function tests, specifically aspartate aminotransferase and alanine aminotransferase (AST and ALT), were reported for five of the patients receiving milacemide, requiring their withdrawal from the study.

Journal of Geriatric Psychiatry and Neurology, Vol. 6, No. 2, 115-119 (1993)
DOI: 10.1177/089198879300600210


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. D. Fakouhi, S. S. Jhee, J. J. Sramek, C. Benes, P. Schwartz, G. Hantsburger, R. Herting, E. A. Swabb, and N. R. Cutler Evaluation of Cycloserine in the Treatment of Alzheimer's Disease J Geriatr Psychiatry Neurol, October 1, 1995; 8(4): 226 - 230. [Abstract] [PDF]